Drug Trial Radar · NCT06406153
Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients
Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Sep 10, 2022
Primary completion
Aug 12, 2023
Study completion Nov 18, 2023
Sponsor
- Lead sponsor
- CinnagenIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase III study is to assess the efficacy and safety of YW17 produced by CinnaGen Company compared to Aldurazyme® in mucopolysaccharidosis type I (MPS I) patients. All patients receive Aldurazyme® for 12 weeks, followed by YW17 for another 12 weeks. The primary outcome is the assessment of the maintenance of the mean uGAG levels at the end of each medication administration. The secondary outcomes are the assessment of 6-minute walking test (6MWT), predicted forced vital capacity (FVC), enzyme activity assay, and adverse events (AEs).
Conditions
- Mucopolysaccharidosis Type 1
Interventions
LaronidaseBiological
Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.
AntihistamineDrug
An antihistamine is administered one hour before the infusion.
AntipyreticDrug
An antipyretic is administered one hour before the infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- mean uGAGTime frame: Baseline, weeks 8, 10, 12, 20, 22, and 24
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine
Mashhad, Iran
Growth and Development Research Center, Childrens Medical Center
Tehran, Iran
Loghman Hospital
Tehran, Iran
Mofid Childrens Hospital
Tehran, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.